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Simeprevir Plus Sofosbuvir (12 and 8Weeks)
in Hepatitis C Virus Genotype 1-Infected
Patients Without Cirrhosis: OPTIMIST-1,
a Phase 3, Randomized Study
Paul Kwo,1 Norman Gitlin,2 Ronald Nahass,3 David Bernstein,4 Kyle Etzkorn,5 Sergio Rojter,6 Eugene Schiff,7 Mitchell Davis,8
Peter Ruane,9 Ziad Younes,10 Ronald Kalmeijer,11 Rekha Sinha,11 Monika Peeters,12 Oliver Lenz,12 Bart Fevery,12
Guy De La Rosa,13 Jane Scott,14 and James Witek11
Effective antiviral therapy is essential for achieving sustained virological response (SVR) in hepatitis C virus (HCV)-
infected patients. The phase 2 COSMOS study reported high SVR rates in treatment-naive and prior null-responder
HCV genotype (GT) 1-infected patients receiving simeprevir1sofosbuvir6ribavirin for 12 or 24 weeks. OPTIMIST-1
(NCT02114177) was a multicenter, randomized, open-label study assessing the efﬁcacy and safety of 12 and 8 weeks of
simeprevir1sofosbuvir in HCV GT1-infected treatment-naive and treatment-experienced patients without cirrhosis.
Patients were randomly assigned (1:1; stratiﬁed by HCV GT/subtype and presence or absence of NS3 Q80K polymor-
phism [GT1b, GT1a with Q80K, GT1a without Q80K]), prior HCV treatment history, and IL28B GT [CC, non-
CC]) to simeprevir 150 mg once daily1sofosbuvir 400 mg once daily for 12 or 8 weeks. The primary efﬁcacy endpoint
was SVR rate 12 weeks after end of treatment (SVR12). Superiority in SVR12 was assessed for simeprevir1sofosbuvir
at 12 and 8 weeks versus a composite historical control SVR rate. Enrolled were 310 patients, who were randomized
and received treatment (n 5 155 in each arm). SVR12 with simeprevir1sofosbuvir for 12 weeks (97% [150/155; 95%
conﬁdence interval 94%-100%]) was superior to the historical control (87%). SVR12 with simeprevir1sofosbuvir for 8
weeks (83% [128/155; 95% conﬁdence interval 76-89%]) was not superior to the historical control (83%). The most
frequent adverse events were nausea, headache, and fatigue (12-week arm: 15% [23/155], 14% [22/155], and 12% [19/
155]; 8-week arm: 9% [14/155], 17% [26/155], and 15% [23/155], respectively). No patients discontinued treatment due
to an adverse event. One (1%, 12-week arm) and three (2%, 8-week arm) patients experienced a serious adverse event
(all unrelated to study treatment). Conclusion: Simeprevir1sofosbuvir for 12 weeks is highly effective in the treatment
of HCV GT1-infected patients without cirrhosis, including those with Q80K. (HEPATOLOGY 2016;64:370-380)
Abbreviations: AE, adverse event; CI, conﬁdence interval; DAA, direct-acting antiviral agent; EOT, end of treatment; GT, genotype; HCV, hepati-
tis C virus; IFN, interferon; OPTIMIST, Optimal Treatment with a sIMeprevIr and Sofosbuvir Therapy; pegIFN, pegylated interferon; PRO,
patient-reported outcome; QD, once daily; RBV, ribavirin; SVR, sustained virological response; SVR4, SVR at 4 weeks after end of treatment;
SVR12, SVR at 12 weeks after end of treatment; SVR24, SVR at 24 weeks after end of treatment.
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The rapid development of new all-oral therapeuticagents for the treatment of hepatitis C virus(HCV) infection has quickly led to the develop-
ment of combination treatment options that are interferon
(IFN)-free and ribavirin (RBV)-free.(1-3) This advance
has resulted in reduced severity and incidence of adverse
events (AEs) and simpler regimens, thereby increasing
adherence.(1) Combination regimens comprising all-oral
direct-acting antiviral agents (DAAs) have demonstrated
high efﬁcacy, with good safety/tolerability proﬁles.(4-6)
One of the ﬁrst IFN-free DAA combination regimens
studied was simeprevir1sofosbuvir6RBV in the phase 2
COSMOS study, the outcomes of which led to the
approval of simeprevir1sofosbuvir for HCV genotype
(GT)1-infected patients.(7) In COSMOS, HCV GT1-
infected prior (pegylated interferon [pegIFN] and RBV)
null responders (METAVIR scores F0-F2), as well as
null responders and treatment-naive patients (META-
VIR scores F3-F4), achieved high rates of sustained viro-
logical response (SVR) 12 weeks after end of treatment
(EOT; SVR12) (90% [72/80] and 94% [82/87], respec-
tively), following simeprevir1sofosbuvir6RBV treat-
ment for 12 or 24 weeks.(7)
Simeprevir is a once-daily (QD), multigenotypic, HCV
NS3/4A protease inhibitor approved in combination with
pegIFN/RBV for chronic HCV GT1 and GT4 infection
in the United States and the European Union. Simeprevir is
also approved in the United States and the European Union
as part of an IFN-free combination with sofosbuvir for
HCVGT1 infection. In addition, simeprevir1sofosbuvir is
approved for HCV GT4 infection and HCV/human
immunodeﬁciency virus coinfection in the EuropeanUnion.
Sofosbuvir is a QD, pangenotypic HCV nucleotide
analog NS5B polymerase inhibitor, approved in com-
bination with pegIFN/RBV, RBV, and the NS5A
inhibitors ledipasvir and daclatasvir.
Data from the phase 3 ION-3 study evaluating
sofosbuvir1ledipasvir in treatment-naive HCV
GT1-infected patients without cirrhosis showed that
patients randomized to the shorter 8-week treatment
achieved a similarly high SVR12 rate to those treated
for 12 weeks (94% versus 95%, respectively), although
relapse rates in the 8-week arm were slightly higher
(5% versus 1%, respectively), indicating that some
patients may beneﬁt from a longer 12-week regimen.(8)
The phase 3 OPTIMIST-1 (Optimal Treatment
with a sIMeprevIr and Sofosbuvir Therapy) trial fur-
ther evaluated the efﬁcacy, safety, and tolerability of
both a 12-week and a shorter 8-week treatment regi-
men of simeprevir1sofosbuvir in treatment-naive and
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treatment-experienced patients with chronic HCV
GT1 infection without cirrhosis.
Patients and Methods
PATIENTS AND STUDY DESIGN
OPTIMIST-1 was a phase 3, multicenter, random-
ized, open-label study initiated on April 17, 2014, at
48 sites in the United States and Canada (Supporting
Fig. S1). The cutoff date for the primary analysis
from which data are presented was January 26, 2015.
The study was approved by the institutional review
board or independent ethics committee at each partic-
ipating center and met the ethical principles of the
Declaration of Helsinki and Good Clinical Practice
guidelines. All patients provided written informed
consent.
Treatment-naive or treatment-experienced (includ-
ing IFN-intolerant) adults (age 18-70 years) with
chronic HCV GT1a/GT1b infection with docu-
mented absence of cirrhosis, plasma HCV RNA
>10,000 IU/mL at screening, and documented IL28B
GT were eligible for inclusion. Treatment-experienced
patients included in the study must have had at least
one documented previous course of IFN-based therapy
with or without RBV. Absence of cirrhosis in enrolled
patients was deﬁned as (1) FibroScan (in countries
where locally approved) result 12.5 kPa within 6
months of screening or between screening and day 1,
(2) FibroTest score 0.48 and aspartate aminotrans-
ferase to platelet ratio index 1 at screening, or (3)
liver biopsy within 2 years of screening, or biopsy
between screening and day 1. If only inﬂammation was
present, laboratory evidence of chronic HCV infection
(anti-HCV antibody or HCV RNA for at least 6
months prior to baseline) had to be provided (Support-
ing Information).
Exclusion criteria included hepatic decompensa-
tion; liver disease of non-HCV etiology; infection/
coinfection with HCV non-GT1a/GT1b, hepatitis
B, or human immunodeﬁciency virus; and signiﬁ-
cant laboratory abnormalities or presence of other
clinically signiﬁcant disease. Patients were also
excluded if they had previously been treated with
any direct-acting anti-HCV agent (approved or
investigational) for chronic HCV infection (Support-
ing Information).
The study consisted of a screening period of up to
6 weeks, followed by 12 or 8 weeks of treatment with
simeprevir (150 mg QD capsule)1sofosbuvir (400 mg
QD tablet). Patients were followed until 24 weeks
after EOT (Supporting Fig. S1 and Supporting
Information).
Dynamic central randomization was implemented.
Patients were randomly assigned 1:1 to 12 or 8 weeks
of treatment (Supporting Information). Randomiza-
tion was stratiﬁed according to HCV GT/subtype
combined with presence or absence of the NS3 Q80K
polymorphism in GT1a patients (1b, 1a without
Q80K, 1a with Q80K), prior HCV treatment history
(treatment-naive/relapsers, nonresponders, IFN-intol-
erant/other), and IL28B GT (CC, non-CC) based on
a polymorphism on chromosome 19 (single-nucleotide
polymorphism rs12979860).
As this was an open-label study, all patients and
investigators were aware of treatment allocations.
PROCEDURES
Blood samples for HCV RNA level determination
were collected at screening; baseline; day 3; weeks 1, 2,
3, 4, 8, and 12; and weeks 4, 12, and 24 of follow-up.
HCV RNA was measured using the Roche COBAS
TaqMan HCV/HPS assay version 2.0 (lower limit of
quantiﬁcation 25 IU/mL, limit of detection 15 IU/mL).
Standard Sanger population-based sequencing (assay
sensitivity 20%-25%) of HCV NS3/4A (considering
positions 43, 80, 122, 155, 156, and 168), NS5A (con-
sidering positions 28, 30, 31, 32, and 93), and NS5B
(considering positions 96, 142, 159, 282, 316, 320, 321,
390, and 415) regions was done at baseline for all
patients. Postbaseline sequencing of HCV NS3/4A and
NS5B was done for those patients not achieving
SVR12. Laboratory (hematology, biochemistry, and uri-
nalysis) tests, vital signs, and physical examinations were
performed regularly during treatment and follow-up.
Electrocardiogram assessments were performed at
screening.
AEs were monitored throughout the study and up
to 4 weeks after planned EOT (Supporting
Information).
Patient-reported outcomes (PROs) were assessed
using three well-validated PRO instruments—the
Fatigue Severity Scale,(9) the Center for Epidemiologic
Studies Depression Scale,(10) and the EuroQoL
5-Dimensions questionnaire(11)—in addition to a new
PRO tool speciﬁcally designed for HCV-infected
patients—the Hepatitis C Symptom and Impact
Questionnaire version 4 (Supporting Information).
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OUTCOMES
The primary efﬁcacy endpoints were to (1) demon-
strate superiority of 12 weeks’ simeprevir (150 mg
QD)1sofosbuvir (400 mg QD) versus a historical con-
trol rate, which was a composite of the highest SVR
rates for approved DAA regimens available at the time
of study design (see below, Statistical Analysis); (2)
demonstrate superiority of 8 weeks’ simepre-
vir1sofosbuvir versus a historical control; and (3) (if
the ﬁrst two objectives were met) evaluate noninferior-
ity of 8 weeks’ versus 12 weeks’ treatment with sime-
previr1sofosbuvir, all with respect to the proportion of
patients achieving SVR12 in the overall population.
Predeﬁned secondary endpoints included SVR rate
4 and 24 weeks after EOT (SVR4 and SVR24, respec-
tively); on-treatment virological response (HCV RNA
<25 IU/mL or undetectable at all time points); on-
treatment failure including viral breakthrough, which
was a stopping rule and deﬁned as conﬁrmed
>1.0 log10 increase in HCV RNA from nadir or con-
ﬁrmed HCV RNA >100 IU/mL in patients who had
previously achieved HCV RNA <25 IU/mL; viral
relapse; SVR12 by prior treatment history and by
selected characteristics (including baseline HCV
RNA); changes from baseline in the HCV NS3/4A
and NS5B sequence in patients not achieving SVR12;
safety and tolerability of 12 or 8 weeks’ simepre-
vir1sofosbuvir; and change from baseline for PRO
assessments at all time points.
An exploratory analysis to investigate SVR12 by
baseline NS5A polymorphisms was also undertaken.
STATISTICAL ANALYSIS
All analyses were performed on the intent-to-treat
population (all randomized patients who received at
least one dose of study drug). The primary analysis was
performed when all patients had completed the
SVR12 visit or had discontinued earlier.
The historical control SVR rates for the 12-week
and 8-week treatment arms (87% and 83%, respec-
tively) were a composite of the highest historical SVR
rates of approved DAA regimens in the subpopula-
tions (available at the time the OPTIMIST-1 study
was designed) depending on the proportion of
treatment-naive, prior relapser, prior nonresponder,
IFN-intolerant, and other patients enrolled in the
study. The SVR rates predeﬁned for each subpopula-
tion are shown in Supporting Table S1.
It was determined that a sample size of 150 patients
per treatment group would provide 90% power to
show superiority in SVR12 rate for the 12-week sime-
previr1sofosbuvir group versus the composite histori-
cal control rate, provided the SVR12 threshold did not
exceed 84%. In addition, the same sample size was
estimated to provide 90% power to show noninferiority
in SVR12 of no more than -12% of the 8-week versus
the 12-week simeprevir1sofosbuvir arm.
The primary objective was tested by means of a
closed testing procedure. To establish that the SVR12
rate achieved with 12 weeks’ simeprevir1sofosbuvir
was superior to the historical control rate, the lower
limit of the 95% conﬁdence interval (CI) for the
SVR12 rate among patients treated for 12 weeks had
to exceed the composite historical control rate of 87%
(Supporting Table S1). Superiority of the 8-week arm
versus the composite historical control rate of 83% was
determined in a similar manner if superiority of the
12-week arm had been established (Supporting
Information).
Secondary efﬁcacy outcomes were analyzed using
descriptive statistics and 95% CIs. All safety data were
summarized descriptively.
Regarding the effect of baseline HCV RNA on
SVR12 rates, the statistical analysis plan identiﬁed
6,000,000 IU/mL and 6,000,000 IU/mL as two cat-
egories of interest. In addition, a post hoc analysis was
                                                                 
FIG. 1. OPTIMIST-1 study proﬁle. At the time of the primary
analysis, 100% of patients had achieved SVR12 or had discontin-
ued earlier. Abbreviations: SMV, simeprevir; SOF, sofosbuvir.
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performed to identify a possible baseline HCV RNA
cutoff that was predictive of achieving a high SVR12
rate (i.e., 95% in patients with baseline HCV RNA
 the cutoff point). A univariate logistic regression
model was ﬁtted, and a receiver operating characteristic
curve was used to determine the predictive value. In
patients treated for 12 weeks, baseline HCV RNA was
not associated with achieving SVR12; and therefore,
TABLE 1. Baseline Demographics and Disease Characteristics (Intent-to-Treat Population)
Characteristic
Simeprevir 150 mg QD1Sofosbuvir 400 mg QD
12 Weeks (n 5 155) 8 Weeks (n 5 155)
Age (years) 56 (19-70) 56 (21-70)
Male 82 (53%) 87 (56%)
Body mass index (kg/m2) 28.0 (16.5-54.5) 26.9 (16.9-56.4)
Race*
White 120 (78%) 125 (81%)
Black/African American 31 (20%) 24 (16%)
Asian 2 (1%) 4 (3%)
Other 1 (<1%) 1 (<1%)
Ethnicity
Hispanic or Latino 24 (15%) 24* (16%)
Prior HCV treatment history†
Treatment-naive 115 (74%) 103 (66%)
Treatment-experienced‡ 40 (26%) 52 (34%)
HCV genotype/subtype and baseline NS3 Q80K polymorphism
1a 116 (75%) 116 (75%)
1a with Q80K§ 46 (40%) 49 (42%)
1a without Q80K§ 70 (60%) 67 (58%)
1b 39 (25%) 39 (25%)
Baseline HCV RNA (log10 IU/mL)
Median (range) 6.83 (3.9-7.9) 6.85 (4.8-7.8)
<4,000,000 IU/mL 56 (36%) 48 (31%)
IL28B genotypejj
CC 43 (28%) 41 (26%)
CT 86 (55%) 86 (55%)
TT 26 (17%) 28 (18%)
METAVIR score#
F0-F2 66 (43) 58 (37)
F3 15 (10) 12 (8)
F4 0 0
PRO scores
FSS** 3.2 (0.14) 2.9 (0.13)
CES-D†† 10.2 (0.71) 8.8 (0.72)
EQ-5D VAS‡‡ 76.7 (1.48) 79.3 (1.53)
HCV-SIQv4 OBSS‡‡ 13.3 (1.01) 10.8 (0.94)
Data are median (range) or n (%) except for PRO scores, which are mean (standard error).
*n 5 154.
†Randomization was stratiﬁed by prior HCV treatment history, as follows: treatment-naive/relapsers, nonresponders, IFN-intolerant/other.
Patients were classiﬁed as “other” if they had received previous pegIFN-based therapy with no on-treatment HCV RNA data available or
undetectable HCV RNA levels within 2 months after end of prior treatment, or had received previous pegIFN-based therapy for <12 weeks
and did not discontinue previous therapy due to pegIFN-related and/or RBV-related AEs, or had received non-pegIFN-based therapy
(IFN with or without RBV), regardless of prior treatment response.
‡Treatment-experienced patients included prior relapsers, prior nonresponders, IFN-intolerant, and other patients (n 5 8, 14, 2, and
16 for the 12-week arm; n 5 13, 10, 11, and 18 for the 8-week arm, respectively). Prior nonresponders included prior null responders,
prior partial responders, and unknown patients (n 5 8, 4, and 2 for the 12-week arm; n 5 5, 1, and 4 for the 8-week arm,
respectively).
§Among HCV GT1a-infected patients.
jjBased on a polymorphism on chromosome 19 (single-nucleotide polymorphism rs12979860).
#Missing METAVIR score data: n 5 74 for the 12-week arm; n 5 85 for the 8-week arm.
**Normal reference value 2.3, range 1-7.
††Normal reference value 16 (lower threshold for depression), range 0-60.
‡‡Normal reference value not available, range 0-100.
Abbreviations: CES-D, Center for Epidemiologic Studies Depression Scale; EQ-5D VAS, EuroQoL 5-Dimensions questionnaire vis-
ual analog scale; FSS, Fatigue Severity Scale; HCV-SIQv4, Hepatitis C Symptom and Impact Questionnaire; OBSS, overall body sys-
tem score.
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establishing a cutoff in this group was not pursued. In
the 8-week arm, a relation between baseline HCV RNA
and achieving SVR12 was observed; and after exploring
a range of cutoff points graphically, baseline HCV RNA
4,000,000 IU/mL was identiﬁed as the optimal cutoff
predictive of response in patients treated with simeprevir
in combination with sofosbuvir for 8 weeks.
Descriptive statistics were used to display the actual
value and change from baseline for each PRO assess-
ment at each time point (including baseline). In addi-
tion, mean changes from baseline in speciﬁc subgroups
were assessed (Supporting Information).
SAS software (version 9.2; SAS Institute Inc., Cary,
NC) was used for all analyses. For the primary end-
point, all statistical tests and 95% CIs were two-sided
with a signiﬁcance level of 0.05.
This trial is registered with clinicaltrials.gov number
NCT02114177.
Results
In total, 375 patients were screened; 310 were
randomized and received at least one dose of treatment
(155 in each arm). At the time of the primary analysis,
all patients had achieved SVR12 or had discontinued
earlier (Fig. 1; Supporting Information).
Baseline demographics and disease characteristics
were well balanced between the treatment arms (Table
1; Supporting Information).
A total of 150 of 155 patients (97%; 95% CI
94%-100%) in the 12-week simeprevir1sofosbuvir
arm achieved SVR12 (Table 2 and Fig. 2). As the
lower limit of the 95% CI of the SVR12 rate in the
12-week arm was greater than the historical control
rate (94% > 87%), superiority was demonstrated (Fig.
2). In the 8-week simeprevir1sofosbuvir arm, 128 of
155 patients (83%; 95% CI 76%-89%) achieved
SVR12. However, superiority over the historical control
was not demonstrated, as the lower limit of the 95% CI
was not greater than the historical control rate
(76% <83%; Fig. 2). As superiority of the 8-week regi-
men versus the historical control was not demonstrated,
noninferiority of this regimen versus 12 weeks of sime-
previr1sofosbuvir was not assessed.
Results for the key secondary efﬁcacy outcomes are
presented in Table 2. There was high concordance
between SVR4 and SVR12 rates in both arms (Table
2). At the time of the primary analysis, ﬁve of ﬁve
(100%) and 39 of 46 (85%) patients in the 12-week
and 8-week arms, respectively, had achieved SVR24.
Table 3 shows SVR12 rates by subgroups of interest.
In the 12-week arm, high SVR12 rates were observed
irrespective of subgroup. In the 8-week arm,
treatment-naive patients achieved SVR12 at a
TABLE 2. Virological Response Over Time (Including SVR12) and
On-Treatment Failure and Viral Relapse Rates (Intent-to-Treat Population)
Response
Simeprevir 150 mg QD1Sofosbuvir 400 mg QD
12 Weeks 95% CI 8 Weeks 95% CI
Week 4 HCV RNA level*
<25 IU/mL undetectable (RVR) 134/153 (88%) 81%-92% 127/154 (82%) 76%-88%
<25 IU/mL detectable 17/153 (11%) 7%-17% 25/154 (16%) 11%-23%
25 IU/mL 2/153 (1%) 0%-5% 2/154 (1%) 0%-5%
SVR4† 150/155 (97%) 93%-99% 130/155 (84%) 77%-89%
SVR12† 150/155 (97%) 94%-100% 128/155 (83%) 76%-89%
On-treatment failure‡ 0 — 0 —
Viral breakthrough§ 0 — 0 —
Viral relapsejj 4/154 (3%) 1%-7% 27/155# (17%) 12%-24%
Data are n/N (%) or 95% CI.
*Missing data due to patients having discontinued all study drugs before week 4 or having missing data at the week 4 time point.
†SVR4 and SVR12 deﬁned as HCV RNA <25 IU/mL detectable or undetectable 4 weeks or 12 weeks, respectively, after EOT.
‡Conﬁrmed HCV RNA <25 IU/mL detectable or 25 IU/mL at EOT.
§Conﬁrmed >1.0 log10 increase in HCV RNA from nadir or conﬁrmed HCV RNA >100 IU/mL in patients who had previously
achieved HCV RNA <25 IU/mL.
jjFailure to achieve SVR with HCV RNA <25 IU/mL undetectable at EOT and HCV RNA 25 IU/mL during the follow-up
period. The incidence of viral relapse was only calculated for patients with undetectable HCV RNA levels at EOT and with at least
one follow-up HCV RNA measurement.
#In the 8-week arm, viral relapse was detected at the ﬁrst follow-up visit (follow-up week 4) for 24/27 (89%) patients, and at the next
follow-up visit (follow-up week 12) for 3/27 (11%) patients.
Abbreviation: RVR, rapid virological response.
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numerically higher rate than treatment-experienced
patients (88 of 103 [85%] versus 40 of 52 [77%],
respectively). GT1b-infected patients and patients
with IL28B CC GT had high SVR12 rates of 92% (36
of 39 patients) and 93% (38 of 41 patients), respec-
tively. Analyses regarding baseline HCV RNA level
showed that patients with HCV RNA
4,000,000 IU/mL achieved an SVR12 rate of 96%
(46 of 48 patients) in the 8-week arm (Table 3). Race,
ethnicity, and body mass index at baseline did not
appear to impact SVR12 rates in either treatment arm
(Supporting Information).
A total of 95/232 (41%) GT1a-infected patients
had an NS3 Q80K polymorphism at baseline, a natu-
rally occurring polymorphism known to confer low-
level resistance to simeprevir in vitro (Table 1).(12) In
the 12-week arm, 44/46 (96%) GT1a-infected patients
with baseline Q80K achieved SVR12 compared with
36/49 (73%) in the 8-week arm (Table 3). Baseline
NS3 polymorphisms associated with simeprevir resist-
ance in vitro other than Q80K were uncommon
(n 5 8) and did not affect outcome; all seven patients
with a baseline NS3 Q80R polymorphism (12-week
arm, n 5 5; 8-week arm, n 5 2) and the one patient
(12-week arm) with an NS3 D168E polymorphism at
baseline achieved SVR12. NS5B substitution S282T
or other polymorphisms associated with resistance to
sofosbuvir were not observed at baseline. Baseline
NS5A polymorphisms had no effect on SVR12 rates
in the 12-week arm, and a numerical difference in
SVR12 rates was observed in the 8-week arm between
patients with and without baseline NS5A polymor-
phisms (Supporting Information).
Among patients who did not achieve SVR12 and
with sequencing data available, emerging NS3 mutations
associated with simeprevir resistance were observed in
one of three (33%; R155K1D168E1I170T) and one
of 25 (4%; I170T) patients in the 12-week and 8-week
arms, respectively (Table 4). Both of these patients were
GT1a-infected and had an NS3 Q80K polymorphism
at baseline. The patient in the 8-week arm also had an
emerging NS5B S282T mutation. No other emerging
NS5B mutations considering the nine NS5B positions
of interest were observed in any other patient not achiev-
ing SVR12.
On-treatment failure, including viral breakthrough,
was not observed in either treatment arm (Table 2).
The main reason for not achieving SVR12 was viral
relapse, which occurred in four of 155 (3%) and 27 of
155 (17%) patients in the 12-week and 8-week arms,
respectively, and was primarily detected at the ﬁrst
follow-up visit 4 weeks after EOT (Table 2).
Viral relapse rates were consistently lower in the
12-week versus 8-week arm across all subgroups
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FIG. 2. SVR12 rates for
patients receiving simeprevir
1sofosbuvir for 12 and 8 weeks
versus historical control rates
(intent-to-treat population). The
primary objective was tested by
means of a closed testing proce-
dure. The 95% Cls were
constructed using a normal
approximation with continuity
correction. To conclude superi-
ority of the SMV1SOF arm
versus the historical data, the
lower limit of the 95% CI of
the SMV1SOF arm had to be
greater than the historical con-
trol rate. Abbreviations: SMV,
simeprevir; SOF, sofosbuvir.
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(Table 3). In the 8-week arm, among patients with
baseline HCV RNA 4,000,000 IU/mL, two of 48
patients (4%) had viral relapse. Both patients were
Black/African American, treatment-naive, with IL28B
TT GT and GT1a infection (one with and one with-
out baseline NS3 Q80K polymorphism) (Supporting
Information).
AEs occurred in a similar proportion of patients in
both treatment arms (Table 5). Two of the grade 3
AEs reported were considered possibly related to study
treatment: pyelonephritis in a patient with a predispos-
ing condition of dysfunctional kidney (12-week arm)
and increased amylase (8-week arm). Serious AEs
occurred in one of 155 (1%; Clostridium difﬁcile colitis)
and three of 155 (2%; gastroesophageal reﬂux disease,
mania, and whiplash) patients in the 12-week and
8-week arms, respectively; none were considered
related to study treatment. The most frequently
reported AEs (10% of patients in either arm) were
nausea, headache, and fatigue (Table 5); all of these
were grade 1 or 2, were transient, and did not lead to
permanent treatment discontinuation. Laboratory
parameter abnormalities are reported in Supporting
Table S2 (see also Supporting Information).
There were no important differences between treat-
ment groups in mean PRO scores at baseline (Table 1;
Supporting Information). Overall, PRO scores
improved from baseline to the week 12 follow-up, but
most changes were not clinically important (Support-
ing Information and Supporting Fig. S3). The mean
change from baseline for all four PRO endpoints
showed greater improvements in patients who achieved
SVR12 versus those who did not (Supporting Infor-
mation and Supporting Table S3).
Discussion
In OPTIMIST-1, 12 weeks of simeprevir
1sofosbuvir in HCV GT1-infected treatment-naive
and treatment-experienced patients without cirrhosis led
to SVR12 rates of 97% overall and demonstrated superi-
ority over the historical control rate (87%), conﬁrming
the high SVR rates achieved in the phase 2 COSMOS
TABLE 3. SVR12 and Relapse Rates by Virological Response at Week 4, Prior Treatment History, HCV GT/Subtype and
Presence of Baseline NS3 Q80K Polymorphism, IL28B Genotype, and Baseline HCV RNA (Intent-to-Treat Population)
Simeprevir 150 mg QD1Sofosbuvir 400 mg QD
SVR12 Viral Relapse*
12 Weeks 95% CI 8 Weeks 95% CI 12 Weeks 95% CI 8 Weeks 95% CI
Week 4 HCV RNA†
<25 IU/mL undetectable 129/134 (96%) 92%-99% 108/127 (85%) 78%-91% 4/133 (3%) 1%-8% 19/127 (15%) 9%-22%
<25 IU/mL detectable 17/17 (100%) 81%-100% 17/25 (68%) 47%-85% 0/17 (0%) 0%-20% 8/25 (32%) 15%-54%
25 IU/mL 2/2 (100%) 16%-100% 2/2 (100%) 16%-100% 0/2 (0%) 0%-84% 0/2 (0%) 0%-84%
Prior treatment history
Treatment-naive 112/115 (97%) 93%-100% 88/103 (85%) 77%-92% 2/114 (2%) 0%-6% 15/103 (15%) 8%-23%
Treatment-experienced 38/40 (95%) 83%-99% 40/52 (77%) 63%-88% 2/40 (5%) 1%-17% 12/52 (23%) 13%-37%
HCV GT/subtype and baseline NS3 Q80K polymorphism
GT1a 112/116 (97%) 91%-99% 92/116 (79%) 71%-86% 3/115 (3%) 1%-7% 24/116 (21%) 14%-29%
GT1a with Q80K 44/46 (96%) 85%-100% 36/49 (73%) 59%-85% 2/46 (4%) 1%-15% 13/49 (27%) 15%-41%
GT1a without Q80K 68/70 (97%) 90%-100% 56/67 (84%) 73%-92% 1/69 (1%) 0%-8% 11/67 (16%) 9%-28%
GT1b 38/39 (97%) 87%-100% 36/39 (92%) 79%-98% 1/39 (3%) 0%-14% 3/39 (8%) 2%-21%
IL28B
CC 43/43 (100%) 92%-100% 38/41 (93%) 80%-99% 0/43 (0%) 0%-8% 3/41 (7%) 2%-20%
CT 83/86 (97%) 90%-99% 72/86 (84%) 74%-91% 2/85 (2%) 0%-8% 14/86 (16%) 9%-26%
TT 24/26 (92%) 75%-99% 18/28 (64%) 44%-81% 2/26 (8%) 1%-25% 10/28 (36%) 19%-56%
Baseline HCV RNA (IU/mL)‡
6,000,000 70/73 (96%) 89%-99% 61/68 (90%) 80%-96% 2/72 (3%) 0%-10% 7/68 (10%) 4%-20%
>6,000,000 80/82 (98%) 92%-100% 67/87 (77%) 67%-85% 2/82 (2%) 0%-9% 20/87 (23%) 15%-33%
4,000,000 54/56 (96%) 88%-100% 46/48 (96%) 86%-100% 1/55 (2%) 0%-10% 2/48 (4%) 1%-14%
>4,000,000 96/99 (97%) 91%-99% 82/107 (77%) 68%-84% 3/99 (3%) 1%-9% 25/107 (23%) 16%-33%
Data are n/N (%) or 95% CI based upon Clopper Pearson approximation.
*The incidence of viral relapse was only calculated for patients with undetectable HCV RNA levels at EOT and with at least one
follow-up HCV RNA measurement.
†Missing data due to patients having discontinued all study drugs prior to, or having missing data at, the week 4 time point.
‡The HCV RNA value of 4,000,000 IU/mL was selected based on a post hoc analysis performed to identify a possible cutoff for base-
line HCV RNA that was predictive for achieving SVR12 in patients treated with 8 weeks of simeprevir1sofosbuvir.
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study.(7) The SVR12 rate in the OPTIMIST-1
12-week arm was similar to those reported in other large
trials with DAA regimens.(6,8,13-17) The SVR12 rate
achieved with 8 weeks of simeprevir1sofosbuvir (83%)
was lower than that observed following 8 weeks of
treatment with sofosbuvir1ledipasvir (94%) in HCV
GT1-infected patients without cirrhosis.(8) However,
this was not a head-to-head comparison, and the
patient populations were different as OPTIMIST-1
included treatment-experienced patients.
Consistently high SVR12 rates (92%) were
observed in all patients treated with 12 weeks of sime-
previr1sofosbuvir, including treatment-experienced
patients and those with baseline characteristics histori-
cally associated with a poor response to HCV treat-
ment (IL28B non-CC GT, high baseline HCV RNA
levels, and historical HCV GT1a infection). Previous
studies demonstrated that the presence of the NS3
Q80K polymorphism at baseline reduced SVR rates
when simeprevir was administered in combination
with pegIFN/RBV.(18,19) The presence of baseline
Q80K polymorphism did not adversely affect SVR12
rates in patients treated with 12 weeks of simepre-
vir1sofosbuvir. In the 8-week arm, lower SVR12 rates
were observed among patients with baseline NS3
Q80K polymorphism compared with those without
Q80K at baseline. In the OPTIMIST-2 study, in
which patients with cirrhosis were treated with a
12-week regimen of simeprevir1sofosbuvir, SVR12
rates were also numerically higher for HCV GT1a-
infected patients without Q80K (92%) versus those
with Q80K (74%).(20) As expected, the presence of
NS5A polymorphisms did not have an impact on the
efﬁcacy of a regimen containing simeprevir and sofos-
buvir (Supporting Information).
Simeprevir1sofosbuvir for 8 weeks led to SVR12
rates of 83% overall but did not achieve superiority ver-
sus the historical control. The main driver for these
lower SVR12 rates was the high proportion of patients
experiencing viral relapse (17% versus 3% in the
12-week arm). Treatment for 12 weeks appeared to
reduce the relapse rate versus the 8-week treatment
group, indicating that treatment duration in the latter
arm was too short. The majority of patients not achiev-
ing SVR12 following 8 weeks of simeprevir1sofosbuvir
had no emerging NS3 mutations at the time of failure.
This suggests that there was insufﬁcient clearance of
intrahepatic wild-type virus in these patients, further
indicating that 8 weeks of treatment was too short.
With the exception of one patient in the 8-week arm,
no emerging NS5B mutations were observed in
OPTIMIST-1, similar to results obtained for the
COSMOS study.(7)
TABLE 5. Summary of AEs During the
Simeprevir1Sofosbuvir Treatment Phase
(Intent-to-Treat Population)
AE
Simeprevir 150 mg QD1
Sofosbuvir 400 mg QD
12 Weeks
(n 5 155)
8 Weeks
(n 5 155)
Any AE 103 (66%) 97 (63%)
Worst grade AE
Grade 1/2 99 (64%) 94 (61%)
Grade 3 3 (2%) 3 (2%)
Grade 4 1 (1%)* 0
Serious AE 1 (1%) 3 (2%)
AE with fatal outcome 0 0
AE leading to permanent
discontinuation†
0 0
Most common AEs‡
Nausea 23 (15%) 14 (9%)
Headache 22 (14%) 26 (17%)
Fatigue 19 (12%) 23 (15%)
AEs of interest
Increased bilirubin 1 (1%) 1 (1%)
Rash (any type) 10 (6%) 12 (8%)
Pruritus (any type) 7 (5%) 9 (6%)
Photosensitivity 2 (1%) 5 (3%)
Dyspnea 3 (2%) 1 (1%)
Data are n (%).
*Elevated gamma-glutamyl transpeptidase levels not related to
simeprevir1sofosbuvir treatment.
†Permanent discontinuation of at least one drug.
‡In 10% of patients in at least one of the two arms.
TABLE 4. NS3 and NS5B Emerging Mutations in Patients
Not Achieving SVR12
Simeprevir 150 mg QD1
Sofosbuvir 400 mg QD
12 Weeks 8 Weeks
Patients with failure* 5/155 (3%) 27/155 (17%)
NS3 sequencing data available† 3/5 (60%) 25/27 (93%)
No emerging NS3 mutations 1/3 (33.3%) 23 (92.0%)
Emerging NS3 mutations‡ 2/3 (66.7%) 2 (8.0%)
I170T 0 1 (4.0%)
R155K1D168E1I170T 1/3 (33.3%) 0
S122G 0 1 (4.0%)
V55A1N174S 1/3 (33.3%) 0
NS5B sequencing data available† 3/5 (3%) 25/27 (17%)
No emerging NS5B mutations 3/3 (100%) 24/25 (96%)
Emerging NS5B mutations§ 0 1/25 (4%)
S282T 0 1/25 (4%)
*All patients not achieving SVR12.
†Only patients with baseline and post-baseline sequencing data
are considered.
‡Amino acid substitutions at NS3 positions 36, 41, 43, 54, 55,
80, 107, 122, 132, 138, 155, 156, 158, 168, 169, 170, 174, and
175 are considered.
§Amino acid substitutions at NS5B positions 96, 142, 159, 282,
316, 320, 321, 390, and 415 are considered.
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Similar to the COSMOS safety results,(7) 12 or 8
weeks of simeprevir1sofosbuvir in OPTIMIST-1 was
generally well tolerated, with the majority of AEs being
clinically manageable. There were no discontinuations
due toAEs and no grade 3 or 4 increases in bilirubin labo-
ratory parameters. No new safety issues were identiﬁed.
PROs were assessed to understand the impact of sime-
previr1sofosbuvir on outcomes that are important from
the patients’ perspective. Patient-reported symptoms and
health-related quality of life improved from baseline to
the week 12 follow-up in both treatment arms. Clinically
important differences were observed between patients
who achieved SVR12 and those who did not in terms of
greater improvement in fatigue scores in both treatment
arms, and in symptoms and health-related quality of life
scores in the 12-week arm. In a pooled analysis based on
pivotal phase 3 simeprevir study results, in which
pegIFN/RBV was used, better PROs were also observed
in patients who achieved SVR12.(21)
In OPTIMIST-1, SVR12 rates were compared
against a composite historical control calculated based
on the highest SVR12 rates obtained with approved
DAA-based regimens available at the time of study
design (all with pegIFN/RBV). This approach is well
established and in accordance with Food and Drug
Administration guidance.(22)
Limitations of the study include the small patient
numbers in certain subgroups, which limited the con-
clusions that could be drawn. The open-label nature of
the study and lack of a comparator arm could also be
viewed as potential limitations.
A strength of the study was that both treatment-naive
and treatment-experienced patients (including prior
relapser, prior partial responder, and null responder
patients) were enrolled. In addition, IFN-intolerant
patients were included (12 of 13 [92%] of whom achieved
SVR12 overall; Supporting Information), and 16% and
18% of patients were Hispanic and Black/African
American, respectively, two populations that have not
been well represented in HCV clinical trials.
In conclusion, the combination of simeprevir and
sofosbuvir for 12 weeks was efﬁcacious and well toler-
ated by treatment-naive and treatment-experienced
patients with chronic HCV GT1 infection without cir-
rhosis, and these ﬁndings further conﬁrm the use of
this regimen in this patient population.
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